A hand holding a bunch of green syringes

Comparing Zepbound Vs Mounjaro

  • Zepbound and Mounjaro (Tirzepatide) are innovative weight loss drugs with dual GIP and GLP-1 receptor agonist mechanisms, regulating blood sugar and inducing weight loss by reducing appetite.1
  • Both medications offer once-weekly dosing and are administered via subcutaneous injection pens, providing convenient options for medical weight loss.
  • A comparison of efficacy between Zepbound and Mounjaro shows promising results for weight loss, although direct head-to-head trials are limited.
  • Common side effects of both drugs include gastrointestinal symptoms, injection site reactions, and metabolic effects, with a boxed warning for the risk of thyroid cancer.
  • Healthcare providers are critical in assessing patient suitability, monitoring treatment progress, and guiding adherence to therapy and lifestyle modifications for effective weight management.

Get At-Home Medical Weight Loss Therapy

Lose weight with FDA-approved semaglutide weight loss injections (the same ingredient in Wegovy & Ozempic). If you are eligible, in-home medical weight loss treatments may help you reach your health goals.

What is Zepbound?

Zepbound, also known as tirzepatide, belongs to the class of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.

Through this dual action, Zepbound regulates blood sugar levels and induces weight loss by reducing appetite and increasing feelings of fullness by slowing down digestion and reducing appetite.

Key benefits of Zepbound include its ability to significantly lower blood sugar levels and promote substantial weight loss in individuals with at least one weight-related condition.

A hand holding a bunch of green syringes

Clinical trials have demonstrated its efficacy in improving glycemic control and reducing body weight, making it a promising option for managing both diabetes and obesity simultaneously.

What is Mounjaro?

Mounjaro operates as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, similar to Zepbound. Its mechanism involves regulating blood sugar levels and inducing weight loss by reducing appetite and increasing feelings of fullness.

Key benefits of Mounjaro include its significant efficacy in lowering blood sugar levels, making it a promising option for individuals with type 2 diabetes. This medication also has the potential to help patients lose weight, although it is not FDA-approved for this purpose.

Zepbound vs. Mounjaro: Comparative Analysis

Zepbound and Mounjaro offer convenient and effective administration with their once-weekly dosing and user-friendly pens. However, patient adherence to the prescribed regimen and lifestyle modifications (e.g., diet and exercise) are essential components of successful weight management strategies.

Both Zepbound and Mounjaro contain the same active ingredient, tirzepatide. However, Zepbound is FDA-approved for weight loss and long-term weight management, while Mounjaro is approved for improving blood sugar levels in people with type 2 diabetes but can be prescribed off-label for weight loss.

In terms of efficacy for weight loss, studies have demonstrated that tirzepatide, the active ingredient in both medications, can lead to considerable weight loss when used as directed.

It’s important to note that direct head-to-head comparisons between Zepbound and Mounjaro are currently limited, as they may not have been studied in the same clinical trials with identical protocols and populations.

Both Zepbound and Mounjaro may cause similar side effects due to their shared active ingredient. Common side effects of these medications may include:

  • Gastrointestinal symptoms: Nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, and gas.
  • Injection site reactions: Such as redness, bruising, itching, or rash at the injection site.
  • Metabolic effects: Low blood sugar (especially when used in combination with other blood sugar-lowering medications).
  • Gallbladder problems: Such as the formation of gallstones.
  • Allergic reactions: Skin rash, itching, or flushing.

Both medications carry a boxed warning regarding the potential risk of thyroid cancer. Patients with a history of thyroid cancer or certain genetic conditions predisposing them to thyroid cancer may be advised against using these medications.

Regarding safety profiles and contraindications, individuals with certain medical conditions or factors may not be suitable candidates for Zepbound or Mounjaro. These may include:

  • History of pancreatitis
  • Severe gastrointestinal conditions
  • Kidney problems

Both medications are available as as a liquid solution in prefilled, single-dose disposable injection pens. Each is administered via subcutaneous injection (under the skin), typically in the upper arm, thigh, or abdomen. The injection site should be rotated every week.

Both medications are typically administered once per week. The specific dosing regimen may involve starting with a lower dose and gradually increasing it over time, as determined by the prescribing healthcare provider.

Adherence to the prescribed dosing schedule is crucial for the effectiveness of these medications in achieving patient goals. Patients are advised to follow their healthcare provider’s instructions carefully and administer the injections as directed.

Both Zepbound and Mounjaro are brand-name medications and do not currently have generic alternatives. The costs of each medication can vary depending on where you purchase your medication, what your insurance covers, and if you have any coupons. Without insurance coverage or prescription assistance programs, the out-of-pocket cost for these medications may be significant.

Insurance coverage for Zepbound and Mounjaro can vary depending on the individual’s insurance plan, formulary, and medical necessity criteria. Some insurance plans may cover these medications partially or in full, while others may require prior authorization or impose restrictions such as step therapy.

Patients are advised to check with their insurance provider to understand their coverage options and potential out-of-pocket expenses for Zepbound or Mounjaro.

Prescription Assistance Programs

The manufacturer of Zepbound and Mounjaro may offer patient assistance programs or savings cards to help eligible individuals reduce their medication costs.

These programs may provide discounts, copay assistance, or other financial support for qualifying patients.

Healthcare Provider Perspectives

From both patient and healthcare provider perspectives, the decision to prescribe medications like Zepbound or Mounjaro involves careful consideration of several factors, including efficacy, safety, patient preferences, and individual health needs.

Prescribing Practices

Healthcare providers, such as primary care physicians, endocrinologists, or obesity specialists, may consider prescribing Zepbound or Mounjaro for eligible patients with obesity or overweight who have not achieved adequate weight loss with lifestyle interventions alone.

They may evaluate factors such as BMI, comorbidities (e.g., type 2 diabetes, cardiovascular risk factors), and patient motivation before initiating treatment.

Patient Management

Healthcare providers play a crucial role in monitoring patients’ response to treatment, assessing weight loss progress, and managing any adverse effects or complications.

They may conduct regular follow-up appointments to track weight changes, adjust medication dosages if necessary, and provide ongoing support and education to promote adherence to therapy and lifestyle modifications.


While both medications have shown effectiveness in promoting weight loss, Zepbound is specifically approved for this purpose, whereas Mounjaro is primarily indicated for improving blood sugar levels in individuals with type 2 diabetes.

Efficacy and safety considerations are paramount when comparing Zepbound and Mounjaro. Since both drugs contain the same active ingredient, tirzepatide, they share similar side effect profiles, most commonly gastrointestinal symptoms. Both medications also carry a boxed warning for the risk of thyroid cancer.

Healthcare providers must carefully assess each patient’s medical history, treatment goals, and potential risks before determining the most suitable option for weight management. Ultimately, individual health needs and medical advice should guide treatment decisions.

Reach Your Weight Loss Goals With Semaglutide

Semaglutide (the same ingredient in Wegovy and Ozempic) is the only proven FDA-approved medication for long-term weight loss and management. Medical weight loss medications can help you on your journey toward your ideal weight.

Book a convenient online consultation and health check followed by a lab test. Eligible individuals will receive a medical weight loss prescription with medications delivered directly to your home.

people doing pilates


[1] Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 5;27(13):4315. doi: 10.3390/molecules27134315. PMID: 35807558; PMCID: PMC9268041.;